RxDoctor Payments Data

Melvin Seek, MD

Nephrology · Ocala, FLNPI 1043218043

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 99.3% of the total across 57 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 21 manufacturers reported payments, led by Abiomed at 45.8% of the total.

$3,402in general payments, 2019–2025

Across 57 payments — averaging $59.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abiomed$2K
  • Nxstage Medical, Inc.$439
  • Outset Medical Inc$297
  • Coala Life Inc$176
  • Baxter Healthcare$173
  • Amarin Pharma, Inc.$134
  • plus $624 from 15 others
$111,605in research payments, 2019–2025

Across 31 payments — averaging $3600.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Quanta Dialysis Technologies Inc$76K
  • Bayer$36K

What the payments were for

  • Food & beverage$3,37799%
  • Education$251%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,402 in reported general payments places this provider in the 70th percentile of 756 nephrology providers in Florida.

See all nephrology providers in Florida →

Medicare billing

Part B allowed, 2024
$364,368
Medicare patients
452
Services billed
2,261

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide21$58,351
OzempicSemaglutide12$12,133
Sevelamer Carbonate35$5,364
Clonidine23$4,537
Calcium Acetate17$1,259
Bumetanide12$1,153
Carvedilol43$920
Minoxidil17$886
Pregabalin19$716
Diltiazem 24hr Er (Cd)Diltiazem Hcl11$658
Amlodipine Besylate56$625
Rosuvastatin Calcium14$535
Losartan Potassium45$494
Lisinopril45$385
Potassium Chloride12$375

Paid to pharmacies, not to this prescriber.

Other nephrology in Ocala

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →